Journal of Medicinal Chemistry · 2000 · 63 citations · 27 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationLead Compound DesignLigand-based DesignPotency OptimizationReceptor PharmacologyStructure-activity Relationship AnalysisAgonist ActivityAntihypertensive PharmacologyLead Compound OptimizationPotency AssaysReceptor Binding OptimizationVasopressin PharmacologyVasopressin Receptor PharmacologyVasopressor Pharmacology
The discovery of a series of nonpeptide arginine vasopressin V(2) receptor agonists is described. After identifying the aniline derivative 8 as our lead compound from the metabolites of compound 7 that showed antidiuretic activity by po administration to Brattleboro rats, improvements in the in vitro potency involving evaluations of the structural requirements for agonist action and optimizing the structure of the benzoyl moiety have been intensively undertaken. These studies led to compounds 16g, 19a, and 23b,h,i that show potent agonist activity for the V(2) receptor.
27
Structure and expression of a human oxytocin receptor
Tadashi Kimura, Osamu Tanizawa, Kensaku Mori et al. · Nature · 1992 · 633 citations
Molecular cloning of the receptor for human antidiuretic hormone
Mariel Birnbaumer, Anita Seibold, S Gilbert et al. · Nature · 1992 · 539 citations
Yoshitaka Yamamura, Hidenori Ogawa, Hiroshi Yamashita et al. · British Journal of Pharmacology · 1992 · 347 citations · Full text
C. Serradeil‐Le Gal, Jean Wagnon, Corinne Garcia et al. · Journal of Clinical Investigation · 1993 · 273 citations · Full text
Medicine, Pharmacology, Physiology +11